Genmab — Januar 2025
-
Sachin Jain’s rating is based on Genmab’s promising pipeline and strategic developments. One of the key factors is the anticipated progress of the HexaBody-CD38, which is set for a critical opt-in decision by JNJ in the first quarter of 2025. This decision will determine the future of the drug, which has shown encouraging data in comparison to Darzalex in multiple myeloma.
Another significant reason for the Buy rating is the potential of Rina-S, -
-
Additionally, the strong launch of Epkinly in late-line patients and its promising expansion into larger indications further supports the Buy recommendation. The company’s confidence in managing liver toxicity issues related to Acasunlimab and the robust overall survival data add to the optimistic outlook for Genmab.
-
CLL is Still in Retreat on My Epcoritamab Trial https://cllsociety.org/2025/01/cll-is-still-in-retreat-on-my-epcoritamab-trial/
-
another small new trial - Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma https://clinicaltrials.gov/study/NCT06575686
-
January 8, 2025
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $50.00 price target on Genmab https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Genmab+AS+(GMAB)/24184756.html -
Godmorgen
-
God morgen
-
slide shows the Evaluate Pharma forecast for Darzalex up to $17.5bn in 2028 https://x.com/BertrandBio/status/1877059350172143702/photo/1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind